Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Naltrexone on Lofexidine PK in Healthy Subjects
NCT02446002Phase 1Completed
- Sponsor
- US WorldMeds
- Start
- May 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lofexidine in opioid withdrawal, sponsored by US WorldMeds. Primary endpoints: Maximum Plasma Concentration (Cmax) for Lofexidine at Day 11, Area Under the Curve (AUC) for Lofexidine at Day 11 and 1 more. Started May 2015; status: completed.
02
Drugs
lofexidine
03
Conditions
opioid withdrawal
Beyond the preview
Go deeper on NCT02446002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446002.